Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DXCM · against 83 other Healthcare companies of similar size
Ranked #41 of 84 · scores higher than 49% of peers
Bars: peers in each 10-point band of the valuation score21 peers with a valuation score of 50–59, including DXCM · Click a bar to see the companies
Its metrics sit close to the Healthcare norm.
| Metric | DXCM | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 81 reported | 3.0% | 2.8% | 54% | 30% | |
| EBITDA yieldHigher is better · 84 reported | 4.6% | 5.1% | 42% | 50% | |
| Free cash flow yieldHigher is better · 56 reported | 4.5% | 3.8% | 62% | 20% | |
| Book yieldHigher is better · 77 reported | 8.4% | 20.1% | 18% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.5B USD | 95 | 60 | |
| 2 | 4.61T JPY (≈$31.3B) | 93 | 76 | |
| 3 | 2.57T JPY (≈$17.5B) | 88 | 62 | |
| 4 | 6.17T JPY (≈$42.0B) | 86 | 70 | |
| 5 | 45.9B USD | 84 | 61 | |
| 39 | 73.2B SAR (≈$19.8B) | 58 | 56 | |
| 39 | 58.6B USD | 58 | 52 | |
| 41 | 8.24T JPY (≈$56.0B) | 57 | 75 | |
| 41 | 54.0B USD | 57 | 47 | |
| 41 | 31.3B USD | 57 | 63 | |
| 44 | 4.25T INR (≈$51.0B) | 56 | 70 | |
| 45 | 45.6B CHF (≈$52.4B) | 55 | 55 | |
| 45 | 48.9B USD | 55 | 54 | |
| 47 | 166.5B SEK (≈$16.6B) | 54 | 49 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score